AMIC vs MACI for knee cartilage repairStandalone microfracture for knee cartilage defects has less than 60% survivorship at three years; AMIC adds a collagen membrane to stabilize repair, whilst MACI uses cultured chondrocytes and shows superiority in the SUMMIT trial for lesions over 3 cm².Standalone microfracture for knee cartilage defects has less than 60% survivorship at three years; AMIC adds a collagen membrane to stabilize repair, whilst MACI uses cultured chondrocytes and shows superiority in the SUMMIT trial for lesions over 3 cm².
What the ChondroFiller evidence actually showsChondroFiller's reoperation rate of 3–8% substantially outperforms microfracture (41%) and ACI/MACI (37%), reflecting its mechanism: the scaffold supports hyaline-like cartilage repair rather than the fibrocartilage scar tissue that other approaches produce.ChondroFiller's reoperation rate of 3–8% substantially outperforms microfracture (41%) and ACI/MACI (37%), reflecting its mechanism: the scaffold supports hyaline-like cartilage repair rather than the fibrocartilage scar tissue that other approaches produce.
How single-stage ACI differs from MACIMACI repairs cartilage defects over two operations, with weeks between them for external cell expansion; STACi compresses the entire process—harvesting, processing, and implantation—into a single surgical session.MACI repairs cartilage defects over two operations, with weeks between them for external cell expansion; STACi compresses the entire process—harvesting, processing, and implantation—into a single surgical session.
Finding a ChondroFiller specialist in the UKChondroFiller provision is concentrated in London specialist centres because its Class III medical device status requires prescription import from Germany, real-time ultrasound-guided placement, and specialist MRI assessment to determine patient suitability.ChondroFiller provision is concentrated in London specialist centres because its Class III medical device status requires prescription import from Germany, real-time ultrasound-guided placement, and specialist MRI assessment to determine patient suitability.
How defect size and age decide OATS or OCADefect size determines whether focal cartilage repair uses autograft (OATS, harvested from the patient's own knee) or donor allograft (OCA): below 2 cm², autograft is viable; above 4 cm², only allograft remains before arthroplasty.Defect size determines whether focal cartilage repair uses autograft (OATS, harvested from the patient's own knee) or donor allograft (OCA): below 2 cm², autograft is viable; above 4 cm², only allograft remains before arthroplasty.
Is ChondroFiller available on the NHSChondroFiller is not available on the NHS anywhere in the UK; patients must access this collagen cartilage scaffold privately, with single injections typically costing around £3,000.ChondroFiller is not available on the NHS anywhere in the UK; patients must access this collagen cartilage scaffold privately, with single injections typically costing around £3,000.
Who qualifies for MACI knee surgeryMACI grows hyaline-like cartilage from the patient's own cells and maintains superior pain and function scores at five years, unlike microfracture, whose fibrocartilage typically deteriorates within two to three years.MACI grows hyaline-like cartilage from the patient's own cells and maintains superior pain and function scores at five years, unlike microfracture, whose fibrocartilage typically deteriorates within two to three years.
Who qualifies for OATS knee surgeryOATS transplants hyaline cartilage harvested from a low-load zone of the same knee to repair focal defects. The donor site heals with fibrocartilage, creating potential for catching, locking, or anterior knee pain.OATS transplants hyaline cartilage harvested from a low-load zone of the same knee to repair focal defects. The donor site heals with fibrocartilage, creating potential for catching, locking, or anterior knee pain.
Who qualifies for a ChondroFiller injectionChondroFiller targets ICRS Grade III–IV cartilage damage, where more than half the cartilage is lost or bone is exposed. Delivered as an ultrasound-guided outpatient injection, the collagen scaffold recruits the patient's own progenitor cells to initiate repair.ChondroFiller targets ICRS Grade III–IV cartilage damage, where more than half the cartilage is lost or bone is exposed. Delivered as an ultrasound-guided outpatient injection, the collagen scaffold recruits the patient's own progenitor cells to initiate repair.
Cartilage Specialist or General Orthopaedic SurgeonFocal cartilage damage—treated with progressive repair techniques from injections to cell-based therapy—warrants a cartilage specialist. Widespread arthritis, fractures, or joint replacement require a general orthopaedic surgeon. Damage type and location, not pain severity, determine which specialist is appropriate.Focal cartilage damage—treated with progressive repair techniques from injections to cell-based therapy—warrants a cartilage specialist. Widespread arthritis, fractures, or joint replacement require a general orthopaedic surgeon. Damage type and location, not pain severity, determine which specialist is appropriate.
Questions that reveal ChondroFiller provider expertiseChondroFiller triggers cartilage repair through a structural scaffold—unlike hyaluronic acid, which lubricates, or corticosteroids, which reduce inflammation. The UK competency gap is wider than for standard injections; correct patient selection demands imaging knowledge and clinical precision.ChondroFiller triggers cartilage repair through a structural scaffold—unlike hyaluronic acid, which lubricates, or corticosteroids, which reduce inflammation. The UK competency gap is wider than for standard injections; correct patient selection demands imaging knowledge and clinical precision.
When cartilage repair makes sense before knee replacementTotal knee replacement achieves over 90% long-term success, yet patients under 55 face substantially higher revision risk within 20 years. For focal cartilage damage in the mid-40s, repair offers a joint-preservation pathway suited to this earlier disease stage—provided defect size and patient profile meet defined clinical criteria.Total knee replacement achieves over 90% long-term success, yet patients under 55 face substantially higher revision risk within 20 years. For focal cartilage damage in the mid-40s, repair offers a joint-preservation pathway suited to this earlier disease stage—provided defect size and patient profile meet defined clinical criteria.